Bdaxit™ is a quality-assured generic of Inlyta® which is a medicine used as a first-line treatment of patients with advanced renal cell carcinoma (RCC) in combination with other medicines. It’s also indicated for the treatment of advanced renal cell carcinoma (RCC) in adult patients who failed 1 prior systemic therapy.
Inlyta Generic (axitinib) – Bdaxit™ 5 Mg
Package Size: 28 Tablets
Active Ingredients: Axitinib 5 MG
Produced by BDR Pharmaceuticals Ltd®